Clinical Utility of Ionised Magnesium for Patients in Critical Care
Magnesium, the second most abundant cation in our body and cofactor for over 600 enzymes. It is involved in controlling various important physiological processes such as antiarrhythmic action, vascular tone action, muscle contraction, glucose metabolism and insulin homeostasis. Monitoring blood magnesium levels is usually done by the total magnesium (tMg); however, the physiologically active fraction of the magnesium is the 'ionised magnesium (iMg).'
In this session, Dr Masaru Yamamoto will uncover the key differences between iMg and tMg, review literature on monitoring methods, and their impact on patient outcomes. Leveraging his extensive experience in clinical chemistry and medical affairs, and his distinguished background at Nova Biomedical, Dr Yamamoto will provide valuable insights into the latest research and its clinical implications.
In this session, Dr Masaru Yamamoto will uncover the key differences between iMg and tMg, review literature on monitoring methods, and their impact on patient outcomes. Leveraging his extensive experience in clinical chemistry and medical affairs, and his distinguished background at Nova Biomedical, Dr Yamamoto will provide valuable insights into the latest research and its clinical implications.
Presenter 1:
Dr Masaru Yamamoto Ph.D.
Director, Asia Pacific, Medical & Scientific Affairs (MASA)
Nova Biomedical
Presenter 2:
Steve Mawditt (Moderator)
National Sales Manager ANZ Nova Biomedical
Date:
6 March 2025
TIme:
Sydney/Melbourne: 5.30PM
Brisbane: 4.30PM
Adelaide: 5.00PM
Perth: 2.30PM
Auckland, NZ: 7.30PM
Brisbane: 4.30PM
Adelaide: 5.00PM
Perth: 2.30PM
Auckland, NZ: 7.30PM
Duration:
1 Hour
Clinical Utility of Ionised Magnesium for Patients in Critical Care
Magnesium, the second most abundant cation in our body and cofactor for over 600 enzymes. It is involved in controlling various important physiological processes such as antiarrhythmic action, vascular tone action, muscle contraction, glucose metabolism and insulin homeostasis. Monitoring blood magnesium levels is usually done by the total magnesium (tMg); however, the physiologically active fraction of the magnesium is the 'ionised magnesium (iMg).'
In this session, Dr Masaru Yamamoto will uncover the key differences between iMg and tMg, review literature on monitoring methods, and their impact on patient outcomes. Leveraging his extensive experience in clinical chemistry and medical affairs, and his distinguished background at Nova Biomedical, Dr Yamamoto will provide valuable insights into the latest research and its clinical implications.
In this session, Dr Masaru Yamamoto will uncover the key differences between iMg and tMg, review literature on monitoring methods, and their impact on patient outcomes. Leveraging his extensive experience in clinical chemistry and medical affairs, and his distinguished background at Nova Biomedical, Dr Yamamoto will provide valuable insights into the latest research and its clinical implications.
Presenter 1:
Dr Masaru Yamamoto Ph.D.
Director, Asia Pacific, Medical & Scientific Affairs (MASA)
Nova Biomedical
Presenter 2:
Steve Mawditt
(Moderator) National Sales Manager ANZ
Nova Biomedical
Date:
6 February 2025
TIme:
Sydney/Melbourne: 7.00PM
Brisbane: 6.00PM
Adelaide: 6.30PM
Perth: 4.00PM
Auckland, NZ: 9.00PM
Brisbane: 6.00PM
Adelaide: 6.30PM
Perth: 4.00PM
Auckland, NZ: 9.00PM
Duration:
1 Hour